News

TSO3 Provides a Commercialization Update

Thursday, October 4, 2018

Myrtle Beach, S.C. and Quebec City, Canada – October 4, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, provided an update regarding the Company’s commercialization of the Company’s STERIZONE® VP4 Sterilizer.  Readers are encouraged to visit the TSO3 website, www.tso3.com, to read the letter to shareholders posted on October 4, 2018, which outlines the Company’s progress to date and provides additional supporting information.

Read more

News

TSO3 Appoints Martin J. Madden to the Board of Directors

Wednesday, August 29, 2018

Myrtle Beach, S.C. and Quebec City, Canada – August 29, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it has appointed Mr. Martin J. Madden to the Company’s board of directors.

Read more

News

UCHealth performs first patient procedure in Colorado using STERIZONE® technology

Monday, August 20, 2018

Loveland, Colo.; Myrtle Beach, S.C.; and Quebec City, Canada – August 20, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, joins with UCHealth, a nationally recognized, nonprofit network of 10 acute care hospitals and more than 150 clinics throughout Colorado, southern Wyoming and western Nebraska, in announcing the first patient procedure in Colorado performed with a duodenoscope sterilized using the STERIZONE® technology.

Read more

News

TSO3 Reports Second Quarter 2018 Results

Tuesday, August 7, 2018

Quebec City, Canada and Myrtle Beach, United States, – August 7, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, reported financial results for the second fiscal quarter ended June 30, 2018.

Read more

News

TSO3 Announces Closing of US$20 million Financing with Courage Capital to Commercialize the STERIZONE® VP4 Sterilizer and Support Getinge Transition

Wednesday, August 1, 2018

Myrtle Beach, United States and Quebec City, Canada August 1st, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices, today announced that TSO3 and a fund (the “Fund”) of which Courage Capital Management LLC, (“Courage”) is the investment advisor, have entered into a binding US$20 million debt financing to fund commercialization initiatives for its STERIZONE® VP4 Sterilizer, the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as certain colonoscopes, gastroscopes and duodenoscopes. Courage is a Nashville, TN headquartered alternative asset management firm with a 20-year track record of investments in health care services, medical devices, and pharmaceuticals.

Read more